Cargando...

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma

BACKGROUND AND AIM: Currently, there is no molecular‐targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u‐HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real‐world study, we aimed to investigate the therap...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JGH Open
Autores principales: Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Sogabe, Msasahiro, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Takayama, Tetsuji
Formato: Artigo
Lenguaje:Inglês
Publicado: Wiley Publishing Asia Pty Ltd 2020
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731817/
https://ncbi.nlm.nih.gov/pubmed/33319048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12408
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!